Literature DB >> 15896974

Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.

Krystyna Pawlak1, Dariusz Pawlak, Michal Mysliwiec.   

Abstract

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), beta-chemokines, increased oxidative stress (SOX) and inflammation have been implicated as important factors in atherosclerosis and vascular remodeling. We hypothesized the possible roles of beta-chemokines [monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory proteins (MIP-1alpha, MIP-1beta) and regulated upon activation, normal T-cell expressed and secreted (RANTES)] as regulators of the metabolism of the vascular extracellular matrix in conditions of increased SOX in hemodialysis (HD) patients. We compared pre-dialysis levels of MMP-9/TIMP-1 system, beta-chemokines, Cu/Zn superoxide dismutase (Cu/Zn SOD) as a marker of SOX and C-reactive protein (CRP) as a marker of inflammation in HD patients with and without cardiovascular disease (CVD) to those of controls. HD patients, particularly those with CVD, showed a significant increase in values of Cu/Zn SOD, CRP, TIMP-1, TIMP-1/MMP-9 ratio, MCP-1 and MIP-1beta, whereas RANTES levels were lower than in the controls. The levels of MIP-1alpha as well as MMP-9 in all HD groups were similar to the controls. The positive correlations were observed between the MMP-9/TIMP-1 system and beta-chemokines, SOX and inflammation in whole HD group and in the subgroup with CVD. Multivariate analysis showed that the duration of dialysis followed by Cu/Zn SOD, MIP-1alpha and beta levels were the significant positive predictors of TIMP-1. In conclusion, our data show that MMP-9/TIMP-1 system and beta-chemokines could cooperate in conditions of elevated SOX, which ultimately predisposes hemodialysis patients to accelerated atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896974     DOI: 10.1016/j.cyto.2004.12.020

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Increased expression of HIF-1alpha, VEGF-A and its receptors, MMP-2, TIMP-1, and ADAMTS-1 at the venous stenosis of arteriovenous fistula in a mouse model with renal insufficiency.

Authors:  Sanjay Misra; Uday Shergill; Binxia Yang; Rajiv Janardhanan; Khamal D Misra
Journal:  J Vasc Interv Radiol       Date:  2010-07-03       Impact factor: 3.464

2.  Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinases as novel stress markers in children and young adults on chronic dialysis.

Authors:  Kinga Musiał; Danuta Zwolińska
Journal:  Cell Stress Chaperones       Date:  2010-09-19       Impact factor: 3.667

3.  Evolution of shear stress, protein expression, and vessel area in an animal model of arterial dilatation in hemodialysis grafts.

Authors:  Sanjay Misra; Alex A Fu; Khamal D Misra; James F Glockner; Debabrata Mukhopadyay
Journal:  J Vasc Interv Radiol       Date:  2010-01       Impact factor: 3.464

4.  Circulating beta chemokine and MMP 9 as markers of oxidative injury in extremely low birth weight infants.

Authors:  Girija Natarajan; Seetha Shankaran; Scott A McDonald; Abhik DAS; Barbara J Stoll; Rosemary D Higgins; Poul Thorsen; Kristin Skogstrand; David M Hougaard; Waldemar A Carlo
Journal:  Pediatr Res       Date:  2010-01       Impact factor: 3.756

5.  Changes in the activity of connective tissue matrix enzymes in the metabolic syndrome.

Authors:  Jolanta Mieczkowska; Jerzy Mosiewicz; Wojciech Barud; Wojciech Kwaśniewski
Journal:  Arch Med Sci       Date:  2011-09-02       Impact factor: 3.318

6.  Adventitial transduction of lentivirus-shRNA-VEGF-A in arteriovenous fistula reduces venous stenosis formation.

Authors:  Binxia Yang; Rajiv Janardhanan; Pawan Vohra; Eddie L Greene; Santanu Bhattacharya; Sarah Withers; Bhaskar Roy; Evelyn C Nieves Torres; Jaywant Mandrekar; Edward B Leof; Debabrata Mukhopadhyay; Sanjay Misra
Journal:  Kidney Int       Date:  2013-08-07       Impact factor: 10.612

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.